Literature DB >> 2866075

Modulation of human colonic arachidonic acid metabolism by sulfasalazine.

C J Hawkey, N K Boughton-Smith, B J Whittle.   

Abstract

The effects of sulfasalazine and its moieties on synthesis of individual products of arachidonic acid metabolism by human colonic mucosa have been investigated. Sulfasalazine inhibited synthesis of the lipoxygenase products. Sulfasalazine and sulfapyridine also inhibited synthesis of thromboxane B2 while enhancing synthesis of prostaglandin (PG) F2 alpha or PGE2, respectively. Inhibition of synthesis of lipoxygenase products and modulation of the profile of cyclooxygenase products could reduce inflammation and enhance mucosal resistance to damage in ulcerative colitis.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2866075     DOI： 10.1007/bf01314051

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


  30 in total

1.  Prostaglandins and chronic diarrhoea: clinical aspects.

Authors:  J Rask-Madsen; K Bukhave
Journal:  Scand J Gastroenterol Suppl       Date:  1979

2.  Distribution studies of salicylazosulfapyridine and its metabolites.

Authors:  M A Peppercorn; P Goldman
Journal:  Gastroenterology       Date:  1973-02       Impact factor: 22.682

3.  Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth.

Authors:  M J Dew; A D Harries; N Evans; B K Evans; J Rhodes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-02

4.  Vasoconstriction with thromboxane A2 induces ulceration of the gastric mucosa.

Authors:  B J Whittle; G L Kauffman; S Moncada
Journal:  Nature       Date:  1981-07-30       Impact factor: 49.962

Review 5.  Pharmacological interactions between prostacyclin and thromboxanes.

Authors:  B J Whittle; S Moncada
Journal:  Br Med Bull       Date:  1983-07       Impact factor: 4.291

6.  The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.

Authors:  A K Azadkhan; S C Truelove; J K Aronson
Journal:  Br J Clin Pharmacol       Date:  1982-04       Impact factor: 4.335

7.  Chemokinetic activity of arachidonic and lipoxygenase products on leuocyctes of different species.

Authors:  R M Palmer; R J Stepney; G A Higgs; K E Eakins
Journal:  Prostaglandins       Date:  1980-08

8.  Biosynthesis of lipoxygenase and cyclo-oxygenase products from [14C]-arachidonic acid by human colonic mucosa.

Authors:  N K Boughton-Smith; C J Hawkey; B J Whittle
Journal:  Gut       Date:  1983-12       Impact factor: 23.059

9.  Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease.

Authors:  P Sharon; W F Stenson
Journal:  Gastroenterology       Date:  1984-03       Impact factor: 22.682

10.  Prostaglandin protection of carbon tetrachloride-induced liver cell necrosis in the rat.

Authors:  J Stachura; A Tarnawski; K J Ivey; T Mach; J Bogdal; J Szczudrawa; B klimczyk
Journal:  Gastroenterology       Date:  1981-08       Impact factor: 22.682
View more
  22 in total

Review 1.  Sulfasalazine. Multiplicity of action.

Authors:  T S Gaginella; R E Walsh
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

2.  Ulcerative colitis: current treatment strategies and future prospects.

Authors:  Sagar Garud; Mark A Peppercorn
Journal:  Therap Adv Gastroenterol       Date:  2009-03       Impact factor: 4.409

Review 3.  Inflammatory intermediaries in inflammatory bowel disease.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Int J Colorectal Dis       Date:  1989       Impact factor: 2.571

4.  Importance of the Evaluation of N-Acetyltransferase Enzyme Activity Prior to 5-Aminosalicylic Acid Medication for Ulcerative Colitis.

Authors:  Andrea L Matthis; Bin Zhang; Lee A Denson; Bruce R Yacyshyn; Eitaro Aihara; Marshall H Montrose
Journal:  Inflamm Bowel Dis       Date:  2016-08       Impact factor: 5.325

Review 5.  Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy.

Authors:  A B Hawthorne; C J Hawkey
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

6.  Inhibition of red cell membrane lipid peroxidation by sulphasalazine and 5-aminosalicylic acid.

Authors:  S M Greenfield; N A Punchard; R P Thompson
Journal:  Gut       Date:  1991-10       Impact factor: 23.059

7.  5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease.

Authors:  Y R Mahida; C E Lamming; A Gallagher; A B Hawthorne; C J Hawkey
Journal:  Gut       Date:  1991-01       Impact factor: 23.059

8.  Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor alpha: a novel mechanism of action of sulphasalazine.

Authors:  S M Greenfield; A S Hamblin; Z S Shakoor; J P Teare; N A Punchard; R P Thompson
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

9.  Acute murine colitis reduces colonic 5-aminosalicylic acid metabolism by regulation of N-acetyltransferase-2.

Authors:  Verónica Ramírez-Alcántara; Marshall H Montrose
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-17       Impact factor: 4.052

10.  Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.

Authors:  O H Nielsen; K Bukhave; J Elmgreen; I Ahnfelt-Rønne
Journal:  Dig Dis Sci       Date:  1987-06       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.